Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Durvalumab + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone is a combination regimen studied for the treatment of high-risk diffuse large B-cell lymphoma (DLBCL). It combines **durvalumab**, a monoclonal antibody immune checkpoint inhibitor targeting PD-L1; **rituximab**, a monoclonal antibody targeting CD20 on B cells; **cyclophosphamide**, an alkylating chemotherapy agent; **doxorubicin**, an anthracycline chemotherapy agent; **vincristine**, a vinca alkaloid disrupting microtubule formation; and **prednisone**, a corticosteroid with immunosuppressive and antitumor effects. This regimen aims to leverage both immune checkpoint blockade and cytotoxic chemotherapy for improved antitumor response. Clinical evidence suggests feasibility and no new safety signals, but no significant efficacy improvement over standard R-CHOP[1].
- Other names
- durvalumab + R-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)DNAGR (Glucocorticoid receptor)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on durvalumab + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.